• Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight
• It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days)
• This monoclonal antibody cocktail received emergency use approval from the Central Drug Standard Control Organization (CDSCO) on May 3rd, 2021
• Apart from India, it has been approved for use in the United States, Switzerland, Germany, Italy, France, and several other countries.Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection should be given either into a vein (intravenously) or below the skin (subcutaneously) by a trained healthcare professional, preferably in a hospital setup
• This is because the use of monoclonal antibodies may cause some side effects that may need immediate medical attention, such as severe allergic reactions (anaphylaxis)
• Patients should be monitored during and at least 1 hour after the injection.
• The most common side effects of this monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting
• If you experience any of these side effects, let your doctor know immediately.
• Before receiving this medicine, let your doctor know if you have any pre-existing medical conditions
• Let the doctor know about your other medications if any, as they may affect or get affected by this COVID-19 drug
• This medicine may be given to pregnant or breastfeeding women after considering its benefits against the risk to the baby or the mother.
• Contact Us
• If you want to know about the medicine availability or need help to identify where you can get it administered, please fill in your details here and we will reach out to you.

Uses of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

• In Treatment of Mild to moderate Coronavirus disease (COVID-19) Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains monoclonal antibodies that help manage mild to moderate COVID-19 symptoms in those individuals who are at a high risk of developing severe COVID-19 infection and do not need oxygen administration
• This medicine may help you to recover from the infection if diagnosed early before hospitalization
• If you think you have come in contact with an infected person, or feel any of the symptoms, consult your doctor immediately.

Missed Doses

If you miss a dose of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, please consult your doctor.

Frequestly asked Questions

What are monoclonal antibodies? How are they relevant to Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection?

Monoclonal antibodies are specific proteins that mimic the immune system’s ability to fight against harmful microorganisms like viruses. Casirivimab and Imdevimab, the monoclonal antibodies present in Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, help protect against the deadly SARS-CoV-2, the virus that causes COVID-19.

What is a monoclonal antibody cocktail?

A monoclonal antibody cocktail is a combination of monoclonal antibodies that are available separately, but are mixed together for use as a cocktail, hence the name.

How are monoclonal antibodies helpful in treating COVID-19?

SARS-CoV-2, the virus that causes COVID-19, has a spike protein on its surface that helps the virus to attach and enter the hu n body. Monoclonal antibodies are engineered to mimic this attachment with SARS-CoV-2, thereby preventing disease progression. Monoclonal antibody therapy may help in treating mild symptoms at the initial stages.

When should monoclonal antibody therapy for COVID-19 be taken?

Monoclonal antibody therapy for COVID-19 should be taken after the early diagnosis of COVID-19 in patients aged 12 years or older with a bodyweight of at least 40 kg. It may also be taken by people who are at a high risk of developing a severe infection, such as those aged 60 years or above, who have comorbidities such as diabetes or hypertension, and those who are immunocompromised.

Who should not take monoclonal antibodies for COVID-19?

Monoclonal antibodies for COVID-19 should not be taken by those who are hospitalized or need oxygen therapy. Additionally, it should not be taken by those under oxygen treatment due to pre-existing comorbidities that may not be associated with COVID-19. Those who are allergic to any of the two medicines in Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection or any of the other ingredients of the kit should also avoid taking this combination of monoclonal antibodies.

Who is at high risk of developing severe COVID-19?

People aged above 60 years, who are obese, have comorbid conditions related to lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients) are at high risk of developing severe COVID-19.

How is Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection used?

Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is given as an injection into a vein (intravenously) or below the skin (subcutaneously), by a healthcare professional, in a hospital to treat mild to moderate symptoms of COVID-19. It should never be injected into a muscle (intramuscularly).

I have high blood pressure and diabetes. Can I take Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection?

Yes, Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection can be taken by patients with high blood pressure or diabetes, if prescribed. As per the available data, the benefits of using monoclonal antibody therapy are more significant than the potential risks.

Common and Known Side effects of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection

• Injection site reactions (pain
• swelling
• redness)
• Fever
• Flushing (sense of warmth in the face
• ears
• neck and trunk)
• Breathlessness
• Chest tightness
• Nausea
• Vomiting